BiotechTube
AMPLY Discovery

AMPLY Discovery

Cambridge, United Kingdom· Est.
amplydiscovery.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

AMPLY Discovery is an AI-driven drug discovery company founded in 2019, headquartered in Cambridge, UK. It has developed the AMPLYfolio AI platform, which mines digitized natural biological data to discover novel peptides, proteins, and RNAi therapeutics, subsequently producing and testing them via a bioprinting and validation pipeline. The company is pre-clinical and pre-revenue, having secured over $3 million in investment and grant funding from entities like Innovate UK. Its approach aims to democratize and accelerate the discovery of new drugs for complex diseases, starting with oncology and anti-infectives.

OncologyInfectious Disease

Technology Platform

AMPLYfolio AI: An integrated platform that digitizes natural biological data via next-generation sequencing, applies proprietary machine learning for compound discovery, and uses high-throughput 'bioprinting' (synthesis) to produce physical peptides, proteins, and RNAi molecules for lab validation.

Opportunities

The massive, unmet need in oncology and antimicrobial resistance (AMR) creates a compelling market for novel therapeutics.
AMPLY's AI-driven platform offers a potentially faster, cheaper, and more productive discovery method compared to traditional approaches, which could attract partnership interest from large pharma seeking to replenish pipelines.
Significant non-dilutive grant funding from UK government bodies provides capital to de-risk the technology without excessive equity dilution.

Risk Factors

The platform is unproven in generating clinical-stage candidates; technical risks include AI model failure or challenges in synthesizing and developing discovered compounds.
The company is pre-revenue and reliant on further investment, with the AMR market posing particular commercial challenges for return on investment.
Competition in AI drug discovery is intense from larger, well-funded players.

Competitive Landscape

AMPLY competes in the crowded AI/ML drug discovery sector with companies like Exscientia, Recursion, and Insilico Medicine. Its differentiation lies in its specific focus on mining natural, evolutionary-derived biological data rather than purely synthetic chemical libraries. It also faces competition from traditional natural product discovery efforts and larger biopharma internal R&D.

More companies in AI / Machine Learning →More companies in United Kingdom →